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A B S T R A C T
Background
Cranberries (particularly in the form of cranberry juice) have been used widely for several decades for the prevention and treatment of
urinary tract infections (UTIs). The aim of this review is to assess the effectiveness of cranberries in treating such infections.
Objectives
To assess the effectiveness of cranberries for the treatment of UTIs.
Search strategy
The search strategy developed by the Cochrane Renal Group was used. Also, companies involved with the promotion and distribution
of cranberry preparations were contacted; electronic databases and the Internet were searched using English and non English language
terms; reference lists of review articles and relevant studies were also searched.
Date of last search: December 2007
Selection criteria
All randomised controlled trials (RCTs) or quasi-RCTs of cranberry juice or cranberry products for the treatment of UTIs. Studies of
men, women or children were included.
Data collection and analysis
Titles and abstracts of studies that were potentially relevant to the review were screened by one author, RJ, who discarded studies that
were clearly ineligible but aimed to be overly inclusive rather than risk losing relevant studies. Authors RJ and LM independently assessed
whether the studies met the inclusion criteria. Further information was sought from the authors where papers contained insufficient
information to make a decision about eligibility.
Main results
No studies were found which fulfilled all of the inclusion criteria. Two studies were excluded because they did not have any relevant
outcomes and two studies are currently being undertaken.
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Authors’ conclusions
After a thorough search, no RCTs which assessed the effectiveness of cranberry juice for the treatment of UTIs were found. Therefore, at
the present time, there is no good quality evidence to suggest that it is effective for the treatment of UTIs. Well-designed parallel group,
double blind studies comparing cranberry juice and other cranberry products versus placebo to assess the effectiveness of cranberry juice
in treating UTIs are needed. Outcomes should include reduction in symptoms, sterilisation of the urine, side effects and adherence to
therapy. Dosage (amount and concentration) and duration of therapy should also be assessed. Consumers and clinicians will welcome
the evidence from these studies.
P L A I N L A N G U A G E S U M M A R Y
Still waiting for evidence about whether cranberries are a useful treatment for urinary tract infections
Cranberries contain a substance that can prevent bacteria from sticking on the walls of the bladder. This may help reduce bladder and
other urinary tract infections (UTIs). Cranberries (usually as cranberry juice) have been used to try and treat UTIs, particularly in high
risk groups such as older people. Cranberries have few adverse effects. The review found no evidence from studies about the effects of
cranberry juice or other cranberry products on UTIs.
B A C K G R O U N D
The term urinary tract infection (UTI) refers to the presence of a
certain threshold number of bacteria in the urine (usually greater
than 100,000/mL). It consists of cystitis (bacteria in the bladder),
urethral syndrome and pyelonephritis (infection of the kidneys).
Lower UTIs involve the bladder, whereas upper UTIs also involve
the kidneys (pyelonephritis). Bacterial cystitis (also called acute
cystitis) can occur inmen and women and the signs and symptoms
include dysuria (pain on passing urine), frequency, cloudy urine,
occasionally haematuria (blood in the urine), and is often associ-
ated with pyuria (urine white cell count greater than 10,000/mL).
Urethral syndrome (frequency and dysuria syndrome) is used to
describe approximately 50%of women with these complaints who
have either nobacterial growth or counts less than100,000 colony-
forming units (cfu)/mL on repeated urine cultures. Pyelonephritis
most commonly occurs as a result of cystitis, particularly in the
presence of transient (occasional) or persistent backflow of urine
from the bladder into the ureters or kidney pelvis (vesicoureteric
reflux). Signs and symptoms include flank pain or back pain, fever,
chills with shaking, general ill feeling plus those symptoms of a
lower UTI. Acute pyelonephritis can be severe in the elderly, in
infants, and in people who are immunosuppressed (for example,
those with cancer or AIDS). Some people have recurrent UTIs
with an average of two to three episodes/year (Roberts 1979;Wong
1984). Children typically present with a high fever and systemic
symptoms such as lethargy (tiredness), vomiting and poor feeding.
Although UTIs can occur in both men and women, they are about
50 timesmore common in adult women than adultmen. Thismay
be because women have a shorter urethra that may allow bacteria
to ascend more easily into the bladder. Symptomatic infection of
the bladder (lower tract UTI) has been estimated to occur in up to
30% of women at some stage during their lives (Kelly 1977). Most
UTIs arise from the ’ascending’ route of infection. The first step is
colonisation of periurethral tissues with uropathogenic organisms,
followed by the passage of bacteria through the urethra. Infection
arises from bacterial proliferation (growth) within the otherwise
sterile urinary tract. In children, UTI occurs more commonly in
boys up to the age of 6 to 12 months, but overall occurs about
three times more often in girls (1% to 3% in boys, 3% to 7% in
girls) (Hellstrom 1991; Winberg 1974).
Cranberries (particularly in the form of cranberry juice) have been
used widely for several decades for the prevention and treatment
of UTIs. Cranberries contain quinic acid, malic acid and citric
acid as well as glucose and fructose. Until recently, it was suggested
that the quinic acid caused large amounts of hippuric acid to be
excreted in the urine which then acted as an antibacterial agent (
Kinney 1979). Several studies, however, have shown no difference
in the levels, or only a transient (short lived) effect thus casting
some doubt on this theory (Kahn 1967; McLeod 1978). More
recently, it has been demonstrated that cranberries prevent bacteria
(particularly E. coli) from adhering (sticking) to uroepithelial cells
2Cranberries for treating urinary tract infections (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
that line the wall of the bladder (Schmidt 1988; Sobota 1984).
Cranberries contain two compounds which inhibit adherence -
fructose and a polymeric compound of unknown nature (Zafriri
1989). Although many juices contain fructose, only cranberries
and blueberries contain the polymeric compound (Ofek 1991).
UTIs are one of the most common medical conditions requiring
outpatient treatment, and complications resulting from persistent
and repeated infections necessitate well over one million hospital
admissions annually in theUSA (Patton 1991). TraditionallyUTIs
have been treated by antibiotic therapy, but these are expensive, can
have side effects and may lead to resistance. The aim of this review
is to assess the effectiveness of cranberries in treating symptomatic
and asymptomatic UTIs. Although cranberry juice is the form of
cranberries most widely used, other cranberry products include
cranberry powder in hard or soft gelatin capsules. The amount
and concentration of cranberry juice needed to be effective for the
treatment of UTIs has not yet been ascertained. One uncontrolled
trial, however, found that over 50% of patients had a positive
clinical response after consuming 450 mL of cranberry juice for
three weeks (Papas 1966).
Cranberries for the prevention of UTIs in susceptible populations
is examined in another review by the same authors (Jepson 2008).
O B J E C T I V E S
We wished to test the following hypotheses:
• Cranberry juice and other cranberry products are more
effective than placebo/no treatment for the treatment UTIs.
• Cranberry juice and other cranberry products are more
effective than any other therapy for the treatment of UTIs.
If studies are included in this review in the future, an attempt will
be made to quantify the side effects of cranberry juice and the
findings will be taken into account in the discussion to determine
the benefit-risk of the treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) of cranberry juice (or
derivatives) versus placebo, no treatment or any other treatment.
Quasi-RCTs (e.g. those studies which randomised participants by
date of birth, or case record number) will be included, but the
quality of the studies will be taken into account during the anal-
ysis. Cross-over studies will be excluded, because they are not ap-
propriate for short term treatment of acute conditions.
Types of participants
Inclusion criteria
Studies of men, women or children with one the following:
1. a symptomatic lower UTI,
2. a symptomatic upper UTI,
3. an asymptomatic UTI.
• Symptomatic is defined as having one or more or the
following symptoms: dysuria, frequency, urgency.
• Studies of participants with either a history recurrent UTIs
or an in-dwelling catheter must have specified that participants
have a confirmed UTI (asymptomatic or symptomatic) prior to
randomisation.
• If studies become available for inclusion in this review, these
three groups will be analysed separately. Furthermore, the
causative organism (e.g. E. coli) and the methods used to
diagnose upper and lower UTIs will be subjected to sensitivity
analysis.
• The participants in the studies can be from any setting
(hospital, clinic, community).
Exclusion criteria
• Studies of the prevention of UTIs in susceptible groups of
the population (these will be analysed in a separate review by the
same authors)
• Studies of any urinary tract condition not caused by
bacterial infection (e.g. interstitial cystitis which is a is a chronic
inflammation of the bladder wall)
Types of interventions
Cranberry juice or a cranberry product (e.g. cranberry capsules)
given for at least five days. If studies become available for inclusion
in this review, dosage (amount and concentration), duration of
treatment and length of treatment will be taken into account in
subgroup analyses (see methods section for more details).
Types of outcome measures
Primary outcome measure
• Number of symptomatic and asymptomatic UTIs in each
group at the end of the treatment period.
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The ’gold standard’ bacteriological criterion for diagnosis of UTI
includes microbiological confirmation from a mid-stream speci-
men of urine (MSU) (or similar method) with greater than 100
000 bacterial cfu/mL, often associated with pyuria (white cells in
the urine). In some situations a bacterial count of less than 100
000 /mL is acceptable (e.g. when a supra-pubic bladder tap or a
catheter urine specimen is obtained). If studies become available
for inclusion in this review, sensitivity analyses will be carried out
on the causative organism (e.g. E. coli), the method of collecting
a specimen of urine (i.e. catheter, MSU or ’clean catch’ specimen)
and the presence of mixed organisms in the urine (which signifies
contamination).
Secondary outcome measures
• Reduction in severity of symptoms.
• Adherence to therapy.
• Side effects.
Search methods for identification of studies
Initial search
Relevant studies were obtained from the following sources:
• The search strategy developed by the Cochrane Renal
Group.
• Cochrane Controlled Trials Register (CCTR) and
CENTRAL (Issue 3 of The Cochrane Library 1998).
• Registry of randomised trials for the Cochrane
Collaboration Field in Complementary Medicine.
• Companies involved with the promotion and distribution
of cranberry preparations were approached and asked to provide
information on both published and unpublished studies.
• Electronic databases including PsycLit, LILACS, CINAHL,
MEDLINE, EMBASE, Biological Abstracts, Current Contents.
These databases were searched using the following terms*:
1. (beverages.sh. or cranberr$.ti,ab or fruit adj5
beverage$.ti,ab. or fruit adj5 drink$.ti,ab. or fruit adj5 juice$ or
vaccinium macrocarpon.ti,ab. or vaccinium oxycoccus.ti,ab. or
vaccinium vitis-idaea.ti,ab.)
2. (UTIs.sh. or cystitis.sh. or bacteriuria.sh. or
pyelonephritis.sh. or UTI$.ti,ab. or urinary adj5 infection$.ti,ab.
or bacter$.ti,ab. or pyelonephrit$.ti,ab. or cystitis.ti,ab.)
3. 1 and 2
(* this is the MEDLINE search strategy. The EMBASE search
expressions are slightly different but the search terms were the
same, except that the term urogenital tract infections was also
searched on as a subject heading.)
• The following terms were searched to identify non-English
language studies:
◦ Danish - (Tranebaersaft.ti,ab. or tranebaer.ti,ab. or
orkaempetranebaer.ti,ab. or store tranebaer.ti,ab. or
cranberry.ti,ab.) and (urinvejsinfektion.ti,ab. or cystitis.ti,ab. or
blaerebetaendelse.ti,ab. or pyelonephritis.ti,ab. or
pyelonefrit.ti,ab.)
◦ Dutch - (veenbes.ti,ab. or lepeltjeheide.ti,ab. or
lepeltjesheide.ti,ab. or Amerikaanse veenbes.ti,ab. or
cranberry.ti,ab.) and (cystitis.ti,ab. or catarrhus.ti,ab. or
vesicalis.ti,ab. or blaasontsteking.ti,ab. or urineweginfectie.ti,ab.
or pyelonephritis.ti,ab. or nephropyelitis.ti,ab.)
◦ French - (canneberges ronce d’Amerique.ti,ab. or
cranberry.ti,ab. or cranberrie.ti,ab.) and (cystite.ti,ab. or
infection urinaire.ti,ab. or pyélonéphrite.ti,ab.)
◦ German - (moosbeere.ti,ab or kranbeere.ti,ab.) and
(zystitis.ti,ab. or cystitis.ti,ab. or harnwegsinfektion.ti,ab. or
harninfekt.ti,ab. or pyelonephritis.ti,ab.)
◦ Italian - (vaccinium oxycoccus.ti,ab. or ossicocco
palustro.ti,ab.) and (cistite.ti,ab. or infezione del tratto
urinario.ti,ab or infezione urinaria.ti,ab. or infezione delle vie
urinarie.ti,ab. or pielonefrite.ti,ab. or nefropielite.ti,ab.)
◦ Portuguese - (cranberry.ti,ab. or oxicoco$.ti,ab. or
vaccinium oxycoccos.ti,ab. or oxycoccus palustris) and
(cistite.ti,ab. or pielonefrite.ti,ab.)
◦ Spanish - (arandano agrio.ti,ab or arandano
americano.ti,ab.) and (cistitis.ti,ab. or infección urinaria.ti,ab or
pielonefritis.ti,ab.)
• The Internet was searched using the terms listed.
• Reference lists of review articles and relevant studies were
searched.
• Conference abstracts from The Proceedings of the
Urological Association (1990-1998), and The Journal of the
American Geriatrics Society (1990 -1998) were searched for
relevant studies.
• The National Research Register was searched for studies
currently underway.
Review update
For this update the Cochrane Renal Group’s specialised register
and CENTRAL was searched. CENTRAL and the Renal Group’s
specialised register contain the handsearched results of conference
proceedings from general and speciality meetings. This is an on-
going activity across the Cochrane Collaboration and is both ret-
rospective and prospective (Master List 2007). Please refer to The
Cochrane Renal Group’s Module in The Cochrane Library for the
complete list of nephrology conference proceedings searched.
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Data collection and analysis
The search strategy described previously was employed to obtain
titles and, where possible, abstracts of studies that were potentially
relevant to the review. The titles and abstracts were screened by
RJ, who discarded studies that were clearly ineligible but aimed to
be overly inclusive rather than risk losing relevant studies. Authors
RJ and LM independently assessed, using full copies of the papers,
whether the studies met the inclusion criteria, with disagreements
resolved by discussion and consultation with the third author JC.
Further information was sought from the authors of papers which
contained insufficient information to make a decision about eli-
gibility.
No studies were found which met all the inclusion criteria. If stud-
ies are found in the future, the quality of all studies that are deemed
eligible for the review will be assessed independently by two of the
authors RJ and LM, with discrepancies resolved by discussion with
the third author JC. The quality of allocation concealment will
be graded as either adequate (A), unclear (B), or inadequate (C),
following the detailed descriptions of these categories provided
by the Cochrane Collaboration. It is intended to use this grading
in investigation of any heterogeneity and in sensitivity analyses.
Other aspects of study quality including the extent of blinding
(if appropriate), whether groups were comparable at baseline, the
extent of losses to follow-up, non-participation, whether the out-
come assessment was standardised, and whether an “intention to
treat” analysis was undertaken, will also be assessed. This infor-
mation will be presented in a table describing the included studies
and provided a context for discussing the reliability of the results.
If studies which meet the inclusion criteria are identified in the
future, RJ will provide LM with the full articles of the included
studies and both authors will independently extract information
using specially designed data extraction forms. For each included
trial, information will be collected regarding the location of the
study, methods of the study (as per quality assessment checklist),
the participants (sex, age, eligibility criteria), the nature of the
interventions, and data relating to the outcomes specified previ-
ously. Where possible, missing data (including side effects) will be
sought from the authors. Discrepancies in the data extraction will
be referred to JC for discussion.
If studies which meet the inclusion criteria are identified in the
future, statistical analyseswill be performedwhere possible. Briefly,
the risk ratio (RR) will be used as the measure of effect for each
dichotomous outcome. Where there is sufficient data, a summary
statistic for each outcome will be calculated using both a fixed
effects and a random effects model. Heterogeneity in the data
will be noted and cautiously explored using previously identified
characteristics of the studies, particularly assessments of quality.
Sensitivity analyses will be undertaken to examine the stability
of the results in relation to a number of factors including study
quality, the source of the data (published or unpublished), the
causative organism (e.g. E.coli), the method used for confirming
the presence of bacteria in the urine (e.g. catheter specimenof urine
or midstream specimen of urine) and the method of diagnosing
upper or lower UTI. Where continuous scales of measurement are
used to assess the effects of treatment, these data will be analysed in
continuous form (i.e. weightedmean difference). If different scales
have been used in different studies, where possible, the results
will be standardised and then combined (i.e. standardised mean
difference).
If studies which meet the inclusion criteria are identified in the
future, the groups described previously (see under types of partic-
ipants) will be analysed separately with the following subgroups:
• dosage (amount and concentration).
• frequency and duration of treatment.
Where possible, we will be seeking data fromwithin studies where
these comparisons have been made, rather than making compar-
isons across studies.
R E S U L T S
Description of studies
See: Characteristics of excluded studies; Characteristics of ongoing
studies.
No studies assessing the treatment ofUTIswith cranberry juice (or
other cranberry products) which met all of the inclusion criteria
were found.
Two studies were excluded from the review. One trial (Nahata
1982) was a randomised cross-over trial, comparing methenamine
mandelate alone, methenamine mandelate plus ascorbic acid, or
methenaminemandelate plus ascorbic acid and cranberry juice for
people with UTIs. No relevant outcomes were presented, however,
and the main purpose of the studies was to see the effect of the
methenamine on formaldehyde concentration. The author was
contacted, but could not provide any further information about
the trial. Another cross-over trial (DuGan 1966) compared cran-
berry juice with no treatment for the reduction of urinary odours
(which could have been caused by a UTI). From the description of
the trial it is unlikely it was randomised and the report contained
no relevant outcomes. See Characteristics of excluded studies for
more details about both these studies.
Two ongoing studies have been identified (Barbosa-Cesnik 2005;
Huang 2007).
• Barbosa-Cesnik 2005 will enrol women aged 18 to 40 years
of age with a culture confirmed UTI. They will be randomised to
either 8 ounces of cranberry juice or placebo juice twice a day for
6 months. Participants will have follow-up visits at 3 and 6
months and whenever they experience a symptomatic episode.
Urine, vaginal and rectal specimens will be taken at each visit to
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test for the presence of bacteria. Participants will complete a
questionnaire at study entry and at day 3, weeks 1 and 2, and
then every month or whenever there is a recurrence of symptoms.
This study is due to be completed in December 2008.
• Huang 2007 will enrol women aged 2-0 to 65 with non-
complicated acute bacterial cystitis. The intervention group will
receive 3-day oral trimethoprim/sulfamethoxazole (80/400 mg)
2 tablets twice a day on day 1 to 3 plus oral compound cranberry
extract tablets (UmayC, 900 mg) 2 tablets three times a day on
day 1 to 7. The control group will received same oral antibiotics
plus identical placebo prescribed as the same protocol of
intervention arm. Outcomes to be assessed are time to symptoms
relief and pyuria eradication rate. This study has not started
recruiting.
Risk of bias in included studies
No studies were found which met the inclusion criteria for this
review.
Effects of interventions
No studies were found which met the inclusion criteria for this
review.
D I S C U S S I O N
No studies assessing cranberries for the treatment of UTIs which
met our inclusion criteria were found. Only a few uncontrolled
studies examining the effectiveness of cranberry juice in treating
the symptoms of UTI have been reported. Two of these did show
a beneficial effect (Papas 1966; Rodgers 1991) but no firm con-
clusions can be drawn from such studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
No RCTs have been performed to assess the effectiveness of cran-
berry juice or cranberry products for the treatment ofUTIs. There-
fore, at the present time, there is no evidence to suggest that cran-
berry juice or other cranberry products are effective in treating
UTIs.
Implications for research
More research is need to assess the effectiveness of cranberry juice
in treating UTIs. Well-designed parallel group, double blind stud-
ies of cranberry juice and other cranberry products for the treat-
ment of UTIs are needed. The outcomes should include reduction
in symptoms, sterilisation of the urine, side effects and adherence
to therapy. Dosage (amount and concentration) and duration of
therapy should also be evaluated. Consumers and clinicians will
welcome the evidence from these studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
DuGan 1966 Cross-over trial of cranberry juice versus no treatment. The 220 participants were elderly and from two hospital
wards - one male and one female. The female ward received the cranberry juice first followed by the male ward.
Cross-over trial of cranberry juice versus no treatment.
This trial was excluded because from the description of the study design, it looked unlikely that this trial had be
randomised. Also, the outcome was urinary odours, and no information was given about urinary tract infections.
Furthermore, cross-over trials may not be a relevant trial design for acute conditions such as urinary tract infections.
Nahata 1982 Randomised controlled cross-over trial of 27 people with bacteriuria comparing methenamine mandelate alone, with
ascorbic acid or with ascorbic acid and cranberry juice. The primary purpose of this review was to assess the effect of
methenamine on formaldehyde concentrations. Each patient was randomised to 5 days of each therapy.
The trial was excluded because it contained no relevant outcomes. Furthermore, cross-over trials may not be a relevant
trial design for acute conditions such as urinary tract infections.
Characteristics of ongoing studies [ordered by study ID]
Barbosa-Cesnik 2005
Trial name or title Cranberry Juice and Urinary Tract Infections
ClinicalTrials.gov identifier: NCT00093054
Methods
Participants 400 Females, 18-40 years with a culture-confirmed urinary tract infection at study start.
Exclusion Criteria:
- Other chronic disease
- Antibiotics within 48 hours prior to study start
- Hospitalization for any reason within 2 weeks prior to study start
- Stones in urinary tract
- Plans to leave Ann Arbor within 6 months after study start
- Allergy to cranberry or cranberry compounds
- Pregnancy
Interventions Participants in this study will be randomly assigned to consume either 8 ounces of cranberry juice or placebo
juice twice a day for 6 months
Outcomes Participants in this study will be randomly assigned to consume either 8 ounces of cranberry juice or placebo
juice twice a day for 6 months. Participants will have follow-up visits at 3 and 6 months, and whenever they
experience a symptomatic episode. Urine, vaginal and rectal specimens will be taken at each visit to test for
the presence of bacteria that cause urinary tract infections. Participants will complete a questionnaire at study
entry, Day 3, Weeks 1 and 2, and monthly thereafter or whenever there is a recurrence of symptoms.
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Barbosa-Cesnik 2005 (Continued)
Starting date November 2004
Contact information Cibele T. Barbosa-Cesnik 734-764-1350 cibele@umich.edu
Notes Expected completion December 2008
Huang 2007
Trial name or title A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Adjuvant Treatment With
Compound Cranberry Extract Tablets (UmayC) in Acute Bacterial Cystitis.
ClinicalTrials.gov identifier: NCT00305071
Methods
Participants 60 females, 20-65 years.
Inclusion Criteria:
- female patient with non-complicated acute bacterial cystitis.
Exclusion Criteria:
- recent (less than one month) urinary tract infection
- partially treated acute cystitis
- anatomical or function disease of the lower urinary tract
- patients received radical pelvic surgery
associated bladder stone disease
- upper urinary tract anomaly or urolithiasis
systemic - infection with body temperature higher than 38°C - known allergic reaction to cranberry or vitamin
C
pregnant or prepare to be pregnant.
Interventions Intervention group will receive 3-day oral trimethoprim/sulfamethoxazole (80/400 mg) 2 tablets twice a day
on day 1 to 3 plus oral compound cranberry extract tablets (UmayC, 900 mg) 2 tablets three times a day on
day 1 to 7. The control group will received same oral antibiotics plus identical placebo prescribed as the same
protocol of intervention arm. For patients with known allergic reaction to sulfa drug, the empirical antibiotics
will be replaced by cephalexin (250 mg) 2 capsules four times a day.
Outcomes Primary Outcome Measures:
- Time to symptoms relief
Secondary Outcome Measures:
- Pyuria eradication rate
Starting date April 2006
Contact information Contact: Po-Chien Huang, MD 886-3-3179599 ext 8223 m001435@e-ms.com.tw
Contact: Hung-Ju Yang, MD 886-3-3179599 ext 8225 m001436@e-ms.com.tw
Notes Not yet recruiting
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D A T A A N D A N A L Y S E S
This review has no analyses.
WH A T ’ S N E W
Last assessed as up-to-date: 18 August 1998.
13 August 2009 Amended Contact details updated.
H I S T O R Y
Protocol first published: Issue 4, 1998
Review first published: Issue 4, 1998
13 May 2009 Amended Contact details updated.
23 September 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
• The titles and abstracts were screened by RJ.
• RJ and LM independently assessed studies.
• Disagreements resolved by discussion and consultation with JC.
• The quality of all studies which were deemed eligible for the review were then assessed independently by two of the reviewers RJ
and LM,.
• Discrepancies resolved by discussion with the third, JC.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Nuffield Trust, UK.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Phytotherapy; Beverages; Fruit [∗therapeutic use]; Urinary Tract Infections [∗therapy]
MeSH check words
Humans
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